Integrating Radioligand Therapy into mCRPC Clinical Practice: From Taiwan and Japan Experience
15 Aug 202512:0013:00
Fumihiko UrabeSpeaker
Jacob See-Tong PangModerator
Ming-Hsin YangSpeaker
Introduce the treatment options and trends for mCRPC (metastatic castration-resistant prostate cancer) medications and share the Xofigo real-world data from Taiwan and Japan.